Back to top
more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$110.83 USD

110.83
1,615,296

-0.11 (-0.10%)

Updated Aug 16, 2024 12:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip

According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.

ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates

ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.

Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View

Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.

Stryker (SYK) Q2 Earnings Beat Estimates, Volume Improves

Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.

Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y

Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.

Cigna (CI) Q2 Earnings Beat on Strong U.S. Commercial Unit

Cigna's (CI) Q2 results reflect solid premium rate hikes and a growing membership base across its U.S. Commercial and Medicare Advantage businesses.

PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View

PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.

Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up

Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.

BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.

Envista (NVST) Q2 Earnings Top Estimates, Margins Expands

Consistent growth in the Specialty Products & Technologies segment and a return to growth in the Equipment & Consumables segment drive Envista's (NVST) Q2 revenues.

Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

STERIS (STE) Q1 Earnings Beat Estimates, Gross Margin Falls

Barring Life Sciences and Dental, rest of STERIS (STE) operating segments report organic revenue growth in fiscal Q1.

McKesson (MCK) Q1 Earnings Beat Estimates, U.S. Sales Strong

McKesson's (MCK) fiscal first-quarter 2024 results benefit from growth in the United States. Divestment hurts the International segment.

Fresenius Medical (FMS) Q2 Earnings and Revenues Beat Estimates

Fresenius Medical's (FMS) second-quarter revenues benefit from strong performance across all segments. Inflationary pressure continues to improve, benefiting operating income.

DENTSPLY SIRONA (XRAY) Beats on Q2 Earnings, Ups '23 EPS View

DENTSPLY SIRONA's (XRAY) Q2 revenues are driven by a rise in demand across key markets, especially in China. Improved pricing and restructuring initiatives boost earnings.

NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down

NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.

CVS Health (CVS) Q2 Earnings Surpass Estimates, Margins Up

Pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health drive CVS Health's (CVS) Q2 revenues.

Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised

Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the second quarter.

Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.

Inspire Medical (INSP) Q2 Earnings & Revenues Top Estimates

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the second quarter.

Exact Sciences (EXAS) Beats on Q2 Earnings, Ups '23 Sales View

Strength in Screening revenues and Precision Oncology drive Exact Sciences (EXAS) Q2 performance.

AmerisourceBergen (ABC) Beats on Q3 Earnings, Ups '23 EPS View

AmerisourceBergen's (ABC) fiscal third-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View

Revvity's (RVTY) second-quarter results reflect the impact of lower COVID-related sales. Both earnings and sales outpace their respective consensus estimate.

Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised

Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.

Tenet Healthcare (THC) Q2 Earnings Beat on Solid Hospital Unit

Tenet Healthcare's (THC) Q2 results gain on improved adjusted admissions and higher pricing yield. Management expects adjusted EPS of $5.18-$6.03 for this year.